Robinson BW, Creaney J, Lake R, et al.
Lancet. 2003; 362(9396):1612-1616.
This publication investigated the serum concentrations of the MESOMARK assay (SMRP) in a group of patients diagnosed with mesothelioma, diagnosed with other cancers, presenting with pleural fluid not related to mesothelioma, diagnosed with lung inflammatory disease and healthy controls.
Results showed that patients diagnosed with mesothelioma had increased concentrations of SMRP compared to patients who were asbestos exposed and the non-asbestos exposed controls. This research also correlated tumor mass with SMRP concentration, in which the concentrations of SMRP are elevated in patients with the largest tumor mass. The authors propose that the use of the SMRP serum value could be useful as an aid in the monitoring of tumor growth.